Bristol-myers Squibb Compnay

Bayer Intellectual Property Gmbh

Leatte R Guernon

Pratik Devasthale

Guohua Zhao

Michael Frederick Parker

Xiaojun Han

Xiang-Yang Ye

Rita Civiello

Kumaravel Selvakumar

Suresh Dhanusu

Swanee E Jacutin-Porte

Palanikumar Balasubramanian

William Johnston Scott

Ronald J Mattson

Jill E Wood

Martin F Hentemann

Zhaoxing Meng

Aniko Redman

Ann-Marie Bullion

Jeffrey Johnson

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to α-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of α-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

3-substituted propionic acids as αV integrin inhibitors

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to &#x3b1;-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ay-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions. 

3-substituted propionic acids as &#x3b1;V integrin inhibitors

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds modulate the mGluR2 receptor and may be useful for the treatment of various disorders of the central nervous system. Formula (I): 

Positive allosteric modulators of mGluR2

This invention relates to novel sulfone 2I3-dihydroimidazo[1 l2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyper-proliferative and/or angiogenesis mediated disorders, as a sole agent or in combination with other active ingredients.

Sulfone substituted 2,3-dihydroimidazo [1,2-C] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis

Growing community of inventors

Moodus, CT, United States of America

Leatte R Guernon